Details for: NAT-ESCITALOPRAM
Company: NATCO PHARMA (CANADA) INC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02440296 | NAT-ESCITALOPRAM | ESCITALOPRAM (ESCITALOPRAM OXALATE) | 10 MG | TABLET | ORAL |
| 02440318 | NAT-ESCITALOPRAM | ESCITALOPRAM (ESCITALOPRAM OXALATE) | 20 MG | TABLET | ORAL |
Summary Reports
Summary Safety Review - Selective Serotonin Reuptake Inhibitors (SSRIs) - Assessing the Potential Risk of Autism
Summary Safety Review - Antidepressants - Assessing the Potential Risk of Serious Eye Disorder (Angle-Closure Glaucoma)
Summary Safety Review - Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-norepinephrine Reuptake Inhibitors (SNRIs) - Assessing the Potential Risk of Sexual Dysfunction despite Treatment Discontinuation
Summary Safety Review - Antidepressants - Assessing the Potential Risk of Serious Eye Disorder (Angle-Closure Glaucoma)
Summary Safety Review - Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-norepinephrine Reuptake Inhibitors (SNRIs) - Assessing the Potential Risk of Sexual Dysfunction despite Treatment Discontinuation
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.